ARWR

Business Context and Reporting Period

Company: Arrowhead Research Corporation (formerly InterActive Group, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2006
Business Model: A development-stage nanotechnology company utilizing a portfolio approach. It operates four majority-owned subsidiaries (Insert Therapeutics, Calando Pharmaceuticals, Unidym, and Aonex Technologies) and funds sponsored research at universities (Caltech, Stanford, Duke, University of Florida) to secure exclusive licensing rights to early-stage technologies in life sciences, electronics, and energy.

Key Financial Metrics

Note: Revenue is derived primarily from grants, development fees, and licensing agreements, not product sales. The company has no debt and maintains significant liquidity.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased from $6.9 million in 2005 to $19.0 million in 2006. This increase is primarily due to higher operating expenses rather than a decline in revenue.
• Operating Expense Growth: Total operating expenses more than doubled to $21.8 million. Key drivers include:
  • Salaries: Increased to $6.5 million (from $2.8 million) due to hiring for R&D, administration, and SOX compliance.
  • R&D Expenses: Increased to $8.6 million (from $3.8 million). This includes a one-time charge of $2.45 million for the acquisition of minority interests in Calando Pharmaceuticals, recorded as in-process R&D expense.
  • Goodwill Impairment: A $999,000 impairment charge was recorded for the subsidiary Aonex Technologies due to a strategic shift toward partnership rather than independent commercialization.
• One-Time Gain in 2005: The 2005 loss was artificially reduced by a $2.3 million gain from the sale of stock in a subsidiary, making the year-over-year loss comparison less indicative of operational trends.

Guidance, Outlook, and Risks

Outlook and Guidance:

• The company does not expect to generate substantial product revenue in the foreseeable future (specifically FY 2007).
• Losses are expected to increase as the company continues to fund R&D, expand staff, and support subsidiary development.
• Management believes current cash reserves ($28 million) are sufficient to fund operations through FY 2007.

Material Risks and Contingencies:

• Development Stage Risk: As a development-stage company, there is no assurance that any technology will achieve commercial viability or regulatory approval (FDA).
• Capital Commitments: The company has committed to provide up to $7 million in additional capital to Calando and $4 million to Unidym based on milestone achievements. Failure to fund these could result in forfeiture of equity interests.
• Regulatory Approval: Subsidiaries Insert and Calando are in clinical/pre-clinical stages. Failure to obtain FDA approval for their drug candidates (IT-101 and CALAA-01) would materially impact the business.
• Stock Volatility: The stock is thinly traded, and the price may fluctuate significantly based on R&D milestones rather than financial performance.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $28 million cash balance against the projected $19 million+ annual loss and future capital commitments to subsidiaries.
• Subsidiary Milestones: Monitor the progress of Insert Therapeutics (Phase I trials for IT-101) and Calando Pharmaceuticals (pre-clinical to IND filing for CALAA-01) as these are critical value drivers.
• Capital Commitments: Review the terms of the $11 million in committed future funding for Calando and Unidym to assess potential dilution or equity forfeiture risks.
• Revenue Recognition: Confirm that revenue remains dependent on grants and licensing fees, with no near-term expectation of product sales.
• Goodwill Impairment: Assess the strategic viability of the Aonex subsidiary following the $999,000 write-off and the shift to a partnership model.